27697 Long-term efficacy, safety, and adherence to tralokinumab treatment in moderate-to-severe atopic dermatitis for up to 3 years: Interim readout of ECZTEND, a phase 3, long-term extension trial

2021 ◽  
Vol 85 (3) ◽  
pp. AB159
Author(s):  
Andrew Blauvelt ◽  
Jean-Philippe Lacour ◽  
Darryl Toth ◽  
Vivian Laquer ◽  
Stefan Beissert ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severe Atopic Dermatitis ◽  
Phase 3 ◽  
Term Efficacy ◽  
Extension Trial

scholarly journals Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders

2021 ◽  
Author(s):  
Jonathan I. Silverberg ◽  
Eric L. Simpson ◽  
Andreas Wollenberg ◽  
Robert Bissonnette ◽  
Kenji Kabashima ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severe Atopic Dermatitis ◽  
Term Efficacy

scholarly journals Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies

2021 ◽  
Vol 5 (6) ◽  
pp. s66
Author(s):  
Eric Simpson ◽  
Leon Kircik ◽  
Andrew Blauvelt ◽  
Michael Kuligowski ◽  
May Venturanza ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Disease Control ◽  
Severe Atopic Dermatitis ◽  
Phase 3 ◽  
Two Phase

N/A

Sign in / Sign up

Export Citation Format

Share Document